Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease

Peripheral Artery Disease: Past and Future

“…More recently, inequities in diagnosis and treatment by race, geography, and socioeconomic status have been identified among people with PAD. 5 In the United States, Black people have an ≈2-fold higher prevalence of PAD compared with White people, and Black patients with PAD have more adverse outcomes, including higher amputation rates, compared with White patients with PAD. 5 Cilostazol is the only drug recommended by guidelines to improve walking performance in PAD, but its effects are modest.…”

“…5 In the United States, Black people have an ≈2-fold higher prevalence of PAD compared with White people, and Black patients with PAD have more adverse outcomes, including higher amputation rates, compared with White patients with PAD. 5 Cilostazol is the only drug recommended by guidelines to improve walking performance in PAD, but its effects are modest. 3 No new drugs have been approved by the US Food and Drug Administration for PAD-related walking impairment since 1999.…”

Stepping Into the Future of Care for Patients With Peripheral Artery Disease

“…2 Investments in clinical trials of patients with PAD by the National Institutes of Health and industry have expanded, and there is greater recognition that PAD and amputation are health equity emergencies in the United States, as exemplified by the fact that Black Americans have >2-fold the rate of amputation compared with other groups. 3 These activities and many others have underscored the sentiment that now is the time for the diagnosis and care for patients with PAD to enter the spotlight as one of the most devastating and underdiagnosed manifestations of atherosclerotic vascular disease.…”